INTU vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-16.
Intuit Inc. · Technology
$279.70
+45.0% upside to fair value
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
INTU has more upside to fair value
(+45.0%).
INTU trades at a lower forward P/E
(16.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
PFE |
| Current Price |
$279.70 |
$25.22 |
| Fair Value Estimate |
$405.56 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$76.5B |
$143.7B |
| Forward P/E |
16.9x
|
19.2x
|
| EV / EBITDA |
11.2x
|
12.3x
|
| Price / Sales |
3.7x
|
2.3x
|
| Price / FCF |
9.9x
|
15.2x
|
| Revenue Growth YoY |
+10.4%
|
+5.4%
|
| Gross Margin |
81.0%
|
69.3%
|
| Operating Margin |
27.5%
|
23.4%
|
| Return on Equity |
23.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
10.08%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Intuit Inc. is a leading technology company specializing in software applications for financial management, including popular products like TurboTax and QuickBooks. The company demonstrates high business quality with a durable competitive moat supported by strong brand recognition, high gross margins of 81%, and a robust return on equity of 23.3%. Despite a moderate revenue growth of 10.4% and ea…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
INTU |
PFE |
| Zone Low |
$304.17 |
$19.44 |
| Zone High |
$344.73 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|